BioSpace News Archive

Sadhale will manage all aspects of formulation development and manufacturing of a client’s clinical trial materials.

Under the terms of the agreement, R+F will be responsible for all development and commercialisation of TPM-based personal care products.

Janssen presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute PASI, as reported through two years of TREMFYA treatment in adult patients with moderate to severe psoriasis.

This new technology allows FMD vaccines to be made without the biosecurity hazard of having actual FMD virus in a U.S. manufacturing facility.

This proof-of-concept study was performed at 25 sites across the U.S.

At 22nd Century, Dr. Tamburrino will assume the role of Vice President of Research and Development upon the retirement, at the end of this month, of Dr. Michael Moynihan.

Neurocrine today announced that new long-term data from the KINECT 4 Phase III open-label study demonstrate that once-daily INGREZZA capsules, the first FDA approved treatment for adults with tardive dyskinesia, improved TD symptoms through 48 weeks of open-label treatment and was generally well tolerated.

Aevi Genomic Medicine announced today the appointment of Matthew D. Bayley, MD, MBA to its Board of Directors.

Jazz Pharmatoday announced the appointment of Daniel N. Swisher, Jr. as president and COO, effective January 3, 2018.

The study will enroll more than 17,000 patients from approximately 1,000 sites around the world to evaluate whether CSL112 reduces cardiovascular events in high-risk patients during the critical 90 days after a heart attack.